Sermonix Pharmaceuticals' Phase 2 Lasofoxifene Trial Poster
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through...
Source: globenewswire.com
Page 8 - Multicenter Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multicenter Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multicenter Study Today - Breaking & Trending Today
Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism
/PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization...
Source: prnewswire.com
Sermonix to Present Updated Data from ELAINE-2 Clinical
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative...
Source: globenewswire.com
Anosmia in pediatric COVID-19
The current paper, published in The Pediatric Infectious Disease Journal, examines the prevalence of anosmia in children with COVID-19 using a smell awareness survey.
Source: news-medical.net
FIREFLY-1 Trial to Test Oral Pan-RAF Inhibitor in Low-Grade Glioma
In a phase 2 study, researchers are evaluating DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma.
Source: cancertherapyadvisor.com